
Marijo Bilusic

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2380867/publications.pdf Version: 2024-02-01



ΜΑΡΙΙΟ ΒΙΓΓΙSIC

#	Article	IF	CITATIONS
1	Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. European Urology, 2015, 68, 959-967.	1.9	395
2	Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. , 2018, 6, 141.		214
3	Immunotherapy of Prostate Cancer: Facts and Hopes. Clinical Cancer Research, 2017, 23, 6764-6770.	7.0	173
4	Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors. , 2019, 7, 240.		162
5	First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors. Clinical Cancer Research, 2019, 25, 99-109.	7.0	116
6	Nivolumab-associated acute glomerulonephritis: a case report and literature review. BMC Nephrology, 2016, 17, 188.	1.8	91
7	Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations. Human Vaccines and Immunotherapeutics, 2017, 13, 2561-2574.	3.3	91
8	Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma. Cancer Immunology, Immunotherapy, 2014, 63, 225-234.	4.2	86
9	Cancer Vaccines. Hematology/Oncology Clinics of North America, 2019, 33, 199-214.	2.2	84
10	Relationships Among Financial Distress, Emotional Distress, and Overall Distress in Insured Patients With Cancer. Journal of Oncology Practice, 2016, 12, e755-e764.	2.5	83
11	Bintrafusp alfa, a bifunctional fusion protein targeting TGF-Î ² and PD-L1, in patients with human papillomavirus-associated malignancies. , 2020, 8, e001395.		79
12	Clinical Evaluation of TRICOM Vector Therapeutic Cancer Vaccines. Seminars in Oncology, 2012, 39, 296-304.	2.2	75
13	Mapping the Genetic Determinants of Hypertension, Metabolic Diseases, and Related Phenotypes in the Lyon Hypertensive Rat. Hypertension, 2004, 44, 695-701.	2.7	56
14	Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 93.e1-93.e11.	1.6	40
15	A phase 2 study of olaparib and durvalumab in metastatic castrate-resistant prostate cancer (mCRPC) in an unselected population Journal of Clinical Oncology, 2018, 36, 163-163.	1.6	35
16	Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines. Cancer Immunology, Immunotherapy, 2012, 61, 109-117.	4.2	34
17	Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report. , 2018, 6, 150.		27
18	Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-Invasive Bladder Cancer: Results of a Phase 2 Trial. European Urology Oncology, 2018, 1, 54-60.	5.4	26

MARIJO BILUSIC

#	Article	IF	CITATIONS
19	Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC). , 2021, 9, e002374.		25
20	Therapeutic Cancer Vaccines. American Journal of Therapeutics, 2012, 19, e172-e181.	0.9	24
21	<p>Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date</p> . Cancer Management and Research, 2020, Volume 12, 7321-7330.	1.9	24
22	Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response. Clinical Cancer Research, 2021, 27, 429-437.	7.0	22
23	Immunotherapy in prostate cancer: Emerging strategies against a formidable foe. Vaccine, 2011, 29, 6485-6497.	3.8	20
24	Anti-angiogenesis in prostate cancer: knocked down but not out. Asian Journal of Andrology, 2014, 16, 372.	1.6	20
25	Small-Cell Carcinoma of the Bladder: 20-Year Single-Institution Retrospective Review. Clinical Genitourinary Cancer, 2017, 15, e337-e343.	1.9	18
26	Current Management Strategy for Metastatic Renal Cell Carcinoma and Future Directions. Current Oncology Reports, 2017, 19, 27.	4.0	16
27	Spontaneous Tumor Lysis Syndrome in Renal Cell Carcinoma: A Case Report. Clinical Genitourinary Cancer, 2014, 12, e225-e227.	1.9	15
28	Editorial: Local Immunotherapy: A Way to Convert Tumors From "Cold―to "Hot― Journal of the National Cancer Institute, 2017, 109, .	6.3	15
29	Molecular Profiling of Exceptional Responders to Cancer Therapy. Oncologist, 2021, 26, 186-195.	3.7	15
30	Early Adolescence and Suicidal Ideations in Croatia. Crisis, 2011, 32, 334-345.	1.2	15
31	A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer. Frontiers in Endocrinology, 2020, 11, 490.	3.5	14
32	Phase II evaluation of the triple combination of PDS0101, M9241, and bintrafusp alfa in patients with HPV 16 positive malignancies Journal of Clinical Oncology, 2021, 39, 2501-2501.	1.6	14
33	Is Extended Pharmacologic Venous Thromboembolism Prophylaxis Uniformly Safe After Radical Cystectomy?. Urology, 2014, 84, 1152-1156.	1.0	12
34	A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1). Prostate Cancer and Prostatic Diseases, 2022, 25, 735-740.	3.9	12
35	Neoadjuvant Immunotherapy: An Evolving Paradigm Shift?. Journal of the National Cancer Institute, 2021, 113, 799-800.	6.3	10
36	Effect of Talactoferrin Alfa on the Immune System in Adults With Non‧mall Cell Lung Cancer. Oncologist, 2013, 18, 821-822.	3.7	9

MARIJO BILUSIC

#	Article	IF	CITATIONS
37	Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer. , 2021, 9, e001556.		9
38	Genetically Hypertensive Brown Norway Congenic Rat Strains Suggest Intermediate Traits Underlying Genetic Hypertension. Croatian Medical Journal, 2008, 49, 586-599.	0.7	8
39	TumorNext: A comprehensive tumor profiling assay that incorporates high resolution copy number analysis and germline status to improve testing accuracy. Oncotarget, 2016, 7, 68206-68228.	1.8	8
40	Combinatorial Natural Killer Cell–based Immunotherapy Approaches Selectively Target Chordoma Cancer Stem Cells. Cancer Research Communications, 2021, 1, 127-139.	1.7	8
41	A Review of Interventional Clinical Trials in Renal Cell Carcinoma: A Status Report From the ClinicalTrials.gov WebSite. Clinical Genitourinary Cancer, 2015, 13, 142-149.	1.9	7
42	The Potential Role for Immunotherapy in Biochemically Recurrent Prostate Cancer. Urologic Clinics of North America, 2020, 47, 457-467.	1.8	7
43	Cabozantinib plus docetaxel and prednisone in metastatic castrationâ€resistant prostate cancer. BJU International, 2021, 127, 435-444.	2.5	7
44	What are the advantages of neoadjuvant immunotherapy over adjuvant immunotherapy?. Expert Review of Anticancer Therapy, 2022, 22, 561-563.	2.4	6
45	A Case of Anti–PD-L1-associated Remitting Seronegative Symmetric Synovitis With Pitting Edema. Clinical Genitourinary Cancer, 2019, 17, e549-e552.	1.9	5
46	Defects in DNA repair genes and sensitivity to cisplatin based neoadjuvant chemotherapy (NAC) for bladder cancer Journal of Clinical Oncology, 2015, 33, 320-320.	1.6	5
47	Immunotherapy for biochemically recurrent prostate cancer Journal of Clinical Oncology, 2018, 36, 215-215.	1.6	5
48	Recurrent Bulbar Paralysis Caused by Botulinum Toxin Type B. Clinical Infectious Diseases, 2008, 46, e72-e74.	5.8	4
49	mpMRI preoperative staging in men treated with antiandrogen and androgen deprivation therapy before robotic prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 352.e25-352.e30.	1.6	4
50	Therapeutic Cancer Vaccines in Prostate Cancer: The Quest for Intermediate Markers of Response. Cancers, 2012, 4, 1229-1246.	3.7	3
51	A phase I/II study of bintrafusp alfa and NHS-IL12 in combination with docetaxel in adults with metastatic castration sensitive (mCSPC) and castration-resistant prostate cancer (mCRPC) Journal of Clinical Oncology, 2021, 39, TPS5096-TPS5096.	1.6	3
52	Fast Clearance of the SARS-CoV-2 Virus in a Patient Undergoing Vaccine Immunotherapy for Metastatic Chordoma: A Case Report. Frontiers in Oncology, 2020, 10, 603248.	2.8	2
53	First-in-human phase I/II trial of PRGN-2009 vaccine as monotherapy or with bintrafusp alfa in patients with recurrent/metastatic (R/M) human papillomavirus (HPV)-associated cancers (HPVC) and as neoadjuvant/induction therapy in locoregionally advanced (LA) HPV oropharyngeal (OP) and sinonasal (SN) squamous cell cancer (SCC) Journal of Clinical Oncology, 2021, 39, TPS6092-TPS6092.	1.6	2
54	Cabazitaxel: a new drug for metastatic prostate cancer. Asian Journal of Andrology, 2011, 13, 185-186.	1.6	2

MARIJO BILUSIC

#	Article	IF	CITATIONS
55	Human capital costs of obtaining oral anticancer medications Journal of Clinical Oncology, 2016, 34, 6506-6506.	1.6	2
56	Avelumab in metastatic castration-resistant prostate cancer (mCRPC) Journal of Clinical Oncology, 2017, 35, 5037-5037.	1.6	2
57	Molecular profiling of cancer outliers Journal of Clinical Oncology, 2017, 35, e13025-e13025.	1.6	2
58	CRLX101 plus olaparib in patients with metastatic castration-resistant prostate cancer Journal of Clinical Oncology, 2018, 36, TPS5096-TPS5096.	1.6	2
59	Patients with undetectable PSA 2 years after docetaxel for metastatic castration sensitive prostate cancer (mCSPC) Journal of Clinical Oncology, 2021, 39, e17044-e17044.	1.6	1
60	Small cell carcinoma of the bladder: Comparison of survival in various treatment modalities at Fox Chase Cancer Center (FCCC) from 1995 to 2015 Journal of Clinical Oncology, 2016, 34, 465-465.	1.6	1
61	Combination of a therapeutic cancer vaccine and immune checkpoint inhibitors in prostate cancer Journal of Clinical Oncology, 2018, 36, 5084-5084.	1.6	1
62	Targeted radionuclides for prostate cancer bone metastases. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 2-6.	1.6	0
63	Castration Resistant Prostate Cancer: Role of Chemotherapy. , 2016, , 509-514.		0
64	A phase 1 open label trial of intravenous administration of MVA-BN-Brachyury vaccine in patients with advanced cancer Journal of Clinical Oncology, 2021, 39, 2617-2617.	1.6	0
65	A phase 1/2, open-label, dose-escalation, safety and tolerability study of NC410 in subjects with advanced or metastatic solid tumors Journal of Clinical Oncology, 2021, 39, TPS2659-TPS2659.	1.6	0
66	Issues in Pre-clinical Models, Clinical Trial Design and Analytical Considerations in Developing and Evaluating Novel Cancer Immunotherapies. , 2013, , 455-474.		0
67	Defects in DNA repair genes and sensitivity to cisplatin based neoadjuvant chemotherapy (NAC) for bladder cancer Journal of Clinical Oncology, 2015, 33, 4514-4514.	1.6	0